Fibrin clot structure - pro-fibrinolytic effect of oral contraceptives in apparently healthy women

Summary

Fibrin metabolism is influenced by many factors. The velocity of fibrin formation, genetic polymorphisms, fibrinolytic features and the structure of the fibrin clot are determinants of fibrin turnover. Oral contraceptives (OCs) have significant impact on the haemostatic system, by increasing the concentration of coagulation factors, plasminogen and tissue plasminogen activator activity, and decreasing the concentration of haemostatic inhibitors. The present study addresses the influence of OCs on fibrin structure and fibrin metabolism. The study included 70 women treated with seven different OC-formulations. Blood was collected at baseline and after six months of OCs. The plasma concentration of fibrinogen, thrombin-antithrombin complex (TAT), plasminogen, plasmin-antiplasmin complex (PAP), D-Dimer and thrombin generation measures were determined. Fibrin structure measures and fibrin clot lysis not affected by the plasma concentration of plasminogen activators and inhibitors were determined. OCs increased the concentration of fibrinogen, TAT, plasminogen, PAP and D-dimer significantly and affected measures of thrombin generation (p<0.001). The maximal optical density of fibrin (p<0.001), the fibrin fibre density (p=0.03), fibrin fibre diameter (p=0.003), fibrin mass-length ratio (p<0.001) and lysis per hour (p<0.001) increased significantly upon OC-treatment. Lysis per hour was not correlated to the concentration of plasminogen. We conclude that the effect of OCs on the coagulation system is balanced by alterations in fibrin structure, facilitating clot lysis and contributing to the fibrinolytic susceptibility already present in women treated with OC. These alterations may counterbalance the OC-induced increased thrombin generation and reduced coagulation inhibitory potential, contributing to maintenance of the haemostatic balance in women receiving OCs.

Keywords

Oral contraceptives - Coagulation - Fibrinolysis - fibrin structure - clot lysis

• References

• 1 Sidelmann JJ, Gram J, Jespersen J. et al. Fibrin clot formation and lysis: basic mechanisms. Semin Thromb Hemost 2000; 26: 605-618
• 2 Sidelmann J, Jespersen J, Gram J. Plasminogen activator activity and plasma-coagulum lysis measured by use of optimized fibrin gel structure preformed in microtiter plates. Clin Chem 1995; 41: 979-985
• 3 Casini A, Duval C, Pan X. et al. Fibrin clot structure in patients with congenital dysfibrinogenaemia. Thromb Res 2016; 137: 189-195
• 4 Ramanathan R, Gram J, Feddersen S. et al. Dusart Syndrome in a Scandinavian family characterized by arterial and venous thrombosis at young age. Scand J Clin Lab Invest 2013; 73: 585-590
• 5 Wolberg AS. Determinants of fibrin formation, structure, and function. Curr Opin Hematol 2012; 19: 349-356
• 6 Ariens RA. Novel mechanisms that regulate clot structure/function. Thromb Res 2016; 141 (02) S25-27
• 7 Ariens RA. Fibrin(ogen) and thrombotic disease. J Thromb Haemost 2013; 11 (01) 294-305
• 8 Bridge KI, Philippou H, Ariens R. Clot properties and cardiovascular disease. Thromb Haemost 2014; 112: 901-908
• 9 Undas A, Zawilska K, Ciesla-Dul M. et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 2009; 114: 4272-4278
• 10 The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. Contraception 2003; 67: 173-185
• 11 Jespersen J. Pathophysiology and clinical aspects of fibrinolysis and inhibition of coagulation. Experimental and clinical studies with special reference to women on oral contraceptives and selected groups of thrombosis prone patients. Dan Med Bull 1988; 35: 1-33
• 12 Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost 1997; 78: 315-326
• 13 Glintborg D, Sidelmann JJ, Altinok ML. et al. Increased thrombin generation in women with polycystic ovary syndrome: A pilot study on the effect of metformin and oral contraceptives. Metabolism 2015; 64: 1272-1278
• 14 Hugon-Rodin J, Alhenc-Gelas M, Hemker HC. et al. Sex hormone-binding globulin and thrombin generation in women using hormonal contraception. Biomarkers 2016: 1-5
• 15 An open label, randomized study to evaluate the effects of seven monophasic oral contraceptive regimens on hemostatic variables. Outline of the protocol. Oral Contraceptive and Hemostasis Study Group. Contraception 1999; 59: 345-355
• 16 Gram J, Jespersen J. A functional plasminogen assay utilizing the potentiating effect of fibrinogen to correct for the overestimation of plasminogen in pathological plasma samples. Thromb Haemost 1985; 53: 255-259
• 17 Sjoland JA, Sidelmann JJ, Brabrand M. et al. Fibrin clot structure in patients with end-stage renal disease. Thromb Haemost 2007; 98: 339-345
• 18 Carr ME, Gabriel DA. The effect of dextran 70 on the structure of plasma-derived fibrin gels. J Lab Clin Med 1980; 96: 985-993
• 19 Carr Jr. ME, Hermans J. Size and density of fibrin fibers from turbidity. Macromolecules 1978; 11: 46-50
• 20 Ryan EA, Mockros LF, Weisel JW. et al. Structural origins of fibrin clot rheology. Biophys J 1999; 77: 2813-2826
• 21 Machlus KR, Cardenas JC, Church FC. et al. Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. Blood 2011; 117: 4953-4963
• 22 Collet JP, Park D, Lesty C. et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 2000; 20: 1354-1361
• 23 Collet JP, Lesty C, Montalescot G. et al. Dynamic changes of fibrin architecture during fibrin formation and intrinsic fibrinolysis of fibrin-rich clots. J Biol Chem 2003; 278: 21331-21335
• 24 Weisel JW, Litvinov RI. The biochemical and physical process of fibrinolysis and effects of clot structure and stability on the lysis rate. Cardiovasc Hematol Agents Med Chem 2008; 6: 161-180
• 25 Li W, Sigley J, Pieters M. et al. Fibrin Fiber Stiffness Is Strongly Affected by Fiber Diameter, but Not by Fibrinogen Glycation. Biophys J 2016; 110: 1400-1410
• 26 Braat EA, Levi M, Bos R. et al. Inactivation of single-chain urokinase-type plasminogen activator by thrombin in human subjects. J Lab Clin Med 1999; 134: 161-167
• 27 Polac I, Borowiecka M, Wilamowska A. et al. Coagulation and fibrynolitic parameters in women and the effects of hormone therapy; comparison of transdermal and oral administration. Gynecol Endocrinol 2013; 29: 165-168
• 28 Foley JH, Kim PY, Mutch NJ. et al. Insights into thrombin activatable fibrinolysis inhibitor function and regulation. J Thromb Haemost 2013; 11 (01) 306-315
• 29 Jespersen J, Kluft C. Decreased levels of histidine-rich glycoprotein (HRG) and increased levels of free plasminogen in women on oral contraceptives low in estrogen. Thromb Haemost 1982; 48: 283-285
• 30 Manzoli L, De Vito C, Marzuillo C. et al. Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis. Drug Saf 2012; 35: 191-205
• 31 Peragallo Urrutia R, Coeytaux RR, McBroom AJ. et al. Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis. Obstet Gynecol 2013; 122: 380-389
• 32 Lidegaard O, Lokkegaard E, Svendsen AL. et al. Hormonal contraception and risk of venous thromboembolism: national follow-up study. Br Med J 2009; 339: b2890